ZyVersa Therapeutics, Inc. (ZVSA) - Cash on Hand per Share

ZyVersa Therapeutics positions itself as a leader in the therapy of renal pathologies through the suppression of inflammation, and analyzing the cash per share metric on GURU.Markets, we note that the current figure is 0.00. Optimizing biochemistry supplies across various laboratories protects future profits. However, a liquidity deficit and early-stage testing force the company to regularly raise capital through share issuances.
Analytical breakdowns for zyversa.com (ZVSA)

This metric reflects the amount of cash per common share, determining the issuer's internal liquidity reserve. By analyzing the level of liquid assets per share, an investor assesses the ability of ZyVersa Therapeutics (ZVSA) to fund costly FDA trials. This resource is critical for protecting margins amidst the patent wars of the biopharmaceutical sector. The stability of this metric confirms the business's financial resilience, whereas excess cash may conversely signal inefficient capital management.